Austar and ATMI open new Chinese manufacturing facility ATMI, Inc. today announced that it offers further prolonged its global biopharma production footprint with the starting of a new Chinese manufacturing facility as part of a joint venture with Austar, a Hong Kong-based comprehensive service provider to the China pharmaceutical industry. The jv, ATMI Austar LifeSciences Limited, originated with the goal of marketing and making high-end, ultra-clean sterile materials packaging for active pharmaceutical substances and sterile pharmaceutical components to meet growing demand across the biopharmaceutical sector in the Asia-Pacific area.Naturally, and directly on cue, the TSA defended its action. As the agency whose significant responsibility it is to deal with national security, TSA must remain vigilant to guard sensitive information in order to secure the nation’s transport systems, said spokesman David A. Castelveter, in a recent statement. This software program is intended to assist in undertaking that mission. This initiative will be utilized relative to all federal laws and regulations and will be reserved for specific situations that meet up with TSA’s qualifications for an insider danger. Legitimate or not really – and we’re gambling not really – TSA officials could be setting the agency up for a repeat of a lawsuit filed by workers against the meals and Drug Administration earlier this year for – you guessed it – spying on them.